Abstract:Oncolytic viruses (OVs) could be the next breakthrough in oncology. The primary objective of this study was to gain a more thorough understanding of OVs in advanced malignancies. This study reviewed 161 clinical studies, including 4,300 patients with advanced cancer. We summarized the antitumor immune response and clinical response to OVs. Moreover, TRAEs, adverse events attributable to OVs, were summarized by grade. 52 (52/161, 32.3%) studies assessed the tumor microenvironment, most of which reported that CD8 + T cells (N = 31) and PD-L1 (N=9) were increased. 60 (60/161, 37.3%) studies reported increased systemic immune responses, including IFN-γ (N=27), IL-6 (N=22) and CD8 + T cells (N=20). A total of 106 (106/161, 65.8%) studies evaluated clinical efficacy in 2,631 patients, with objective response and disease control rates of 621 (23.6%) and 1603 (60.9%), respectively. Subgroup analysis showed an objective response in 352 (30.8%) and disease control in 704 (62.2%) of 1143 patients in the HSV subgroup. The percentages of patients with objective response and disease control for different administration routes, including intratumoral injection (25.8%; 62.2%) and intravenous injection (20.2%; 56.8%), and for different treatment options, including combination therapy (31.3%; 69.8%) and OVs monotherapy (17.8%; 54.3%), were summarized. For different combination therapies, OVs plus immunotherapy may be promising, with objective response and disease control at elevated proportions (39.6%; 66.3%). Moreover, OVs demonstrated a manageable safety profile, with most TRAEs being grade 1-2. In summary, OVs that activate innate and specific immune responses that ultimately enhance the antitumor response deserve further investigation.

Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment

Recent advances in targeting cancer stem cells using oncolytic viruses

Mesenchymal Stem Cells Engineered by Nonviral Vectors: A Powerful Tool in Cancer Gene Therapy

Efficacy and Safety of Oncolytic Virus Immunotherapy in Advanced Malignancies: A Systematic Review of 161 Clinical Studies

Mesenchymal stem cells as carrier cells to enable effective intratumoral delivery of oncolytic virus for oncolytic virotherapy: a systematic review

Oncolytic virus therapy for malignant gliomas: entering the new era

The emerging field of oncolytic virus-based cancer immunotherapy

Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses

Oncolytic virus therapy in cancer: A current review

Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy

Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy

Therapeutic potential of oncolytic viruses in the era of precision oncology

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

Oncolytic Herpes Simplex Virus-Based Therapies for Cancer

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

Oncolytic Viruses in Cancer Immunotherapy

Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment

Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response